Kromek Group plc Stocks

£ 10.4Last Updated 09.04.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

£ 92.17M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 10.4
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection components and devices for the medical imaging, civil nuclear industry, CBRNe security, and safety screening markets in the United Kingdom, North America, Asia, Europe, Australasia, and Africa. The company's products provide high-resolution information on material composition and structure that are used in various applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, as well as the analysis of radioactive materials. It also offers civil nuclear radiation detection products, which include gamma radiation and neutron detectors, high-specification, high-resolution devices, components, and software for nuclear detection problems, as well as offers a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator technology for gamma-ray, x-ray, and neutron detection. In addition, the company provides medical imaging products, including CZT gamma detectors for SPECT imaging, CZT bone mineral densitometry detectors, and photon-counting spectral CT systems. Further, it offers CBRNE homeland security products and solutions for government, border control, airport and seaports, HazMat teams, ambulance crews, police, and armed forces, as well as a range of gamma spectroscopy software that enables specialized gamma-ray spectroscopy for the analysis of samples. Additionally, the company provides CZT imaging development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array for laboratory and research imaging; and engages in the scientific research and development activities. It sells its products through distributors, OEMs, and direct sales. The company was incorporated in 2013 and is headquartered in Sedgefield, the United Kingdom.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of KMK.L is 22 and suggests 114% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks